Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Lysosomes01:31

Lysosomes

Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
Lysosomes01:31

Lysosomes

Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Cell Ontology in the age of single-cell omics.

Scientific data·2026
Same author

Population differences in wearable device wear time: Rescuing data to address biases and advance health equity.

medRxiv : the preprint server for health sciences·2026
Same author

IL-6 Receptor Antagonists and Severe Post-COVID-19 Outcomes: An Emulated Target Trial.

medRxiv : the preprint server for health sciences·2026
Same author

Systematic benchmarking demonstrates large language models have not reached the diagnostic accuracy of traditional rare-disease decision support tools.

European journal of human genetics : EJHG·2026
Same author

A custom phenotypic profile for Fanconi anemia: Addressing gaps in existing disease annotations.

medRxiv : the preprint server for health sciences·2026
Same author

Epilepsy disease classification: a community effort to enhance the Mondo Disease Ontology.

Database : the journal of biological databases and curation·2026
Same journal

Predicting Chemotherapy Response from Staging Laparoscopy Images.

medRxiv : the preprint server for health sciences·2026
Same journal

Development and External Validation of a Machine Learning Model for 10-Year Ischemic Stroke Risk Prediction in Diverse Populations.

medRxiv : the preprint server for health sciences·2026
Same journal

MCH-Guard: Multimodal Machine Learning Framework for Risk Stratification of Cerebral Microhemorrhage Risk in the Alzheimer's Disease Neuroimaging Initiative.

medRxiv : the preprint server for health sciences·2026
Same journal

Genetic and maternal environmental contributions to estimated fetal weight at 20 weeks gestation compared with birthweight.

medRxiv : the preprint server for health sciences·2026
Same journal

Better immediate declarative memory is associated with forgetting during locomotor adaptation in chronic stroke and in older adults.

medRxiv : the preprint server for health sciences·2026
Same journal

An empirical Bayes framework for burden and dispersion association tests helps prioritize rare variants associated with Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Differential COVID-19 Outcomes Across Lysosomal Disorders.

Blake K Byer, Zachary Butzin-Dozier, Brenda M McGrath

    Medrxiv : the Preprint Server for Health Sciences
    |July 3, 2026
    PubMed
    Summary
    This summary is machine-generated.

    Individuals with lysosomal disorders (LDs) face higher odds of COVID-19 hospitalization, particularly those with neurodegenerative types. However, LDs do not worsen survival rates once hospitalized, highlighting the need for personalized care.

    More Related Videos

    Dual-color Correlative Light and Electron Microscopy for the Visualization of Interactions between Mitochondria and Lysosomes
    10:25

    Dual-color Correlative Light and Electron Microscopy for the Visualization of Interactions between Mitochondria and Lysosomes

    Published on: September 27, 2024

    Related Experiment Videos

    Last Updated: Jul 4, 2026

    In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
    10:16

    In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

    Published on: December 20, 2017

    Dual-color Correlative Light and Electron Microscopy for the Visualization of Interactions between Mitochondria and Lysosomes
    10:25

    Dual-color Correlative Light and Electron Microscopy for the Visualization of Interactions between Mitochondria and Lysosomes

    Published on: September 27, 2024

    Area of Science:

    • Rare inherited diseases
    • Infectious disease epidemiology
    • Genetics and genomics

    Background:

    • Lysosomal disorders (LDs) are rare inherited conditions impacting multiple systems.
    • LDs present concerns for severe COVID-19 due to comorbidities.
    • SARS-CoV-2's reliance on endolysosomal pathways suggests potential LD protective effects, creating conflicting hypotheses.

    Purpose of the Study:

    • To investigate the association between lysosomal disorders and COVID-19 outcomes.
    • To resolve conflicting hypotheses regarding LDs' impact on SARS-CoV-2 infection.
    • To estimate population-level outcomes using large-scale health data.

    Main Methods:

    • Retrospective cohort study utilizing nationwide U.S. electronic health records (N3C).
    • Inclusion of longitudinal records from January 1, 2018, to July 11, 2024.
    • Comparison of 5,460 patients with LDs against 10,920 matched controls for COVID-19 outcomes.

    Main Results:

    • Patients with LDs had 1.86 times higher odds of COVID-19 hospitalization (95% CI: 1.70-2.04).
    • Neurodegenerative LDs (e.g., neuronal ceroid lipofuscinosis, metachromatic leukodystrophy) showed significantly elevated hospitalization odds, even after comorbidity adjustment.
    • Hospitalized LD patients had comparable one-year survival rates (82.1%) to controls (82.0%).

    Conclusions:

    • Lysosomal disorders increase COVID-19 hospitalization odds, influenced by comorbidities and specific LD effects.
    • The primary excess risk associated with LDs is in the transition to hospitalization.
    • Personalized clinical management is recommended for LD patients to mitigate COVID-19 consequences.